<DOC>
	<DOCNO>NCT00086684</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness pentosan polysulfate sodium 100 mg day , pentosan polysulfate sodium 100 mg three time day , placebo 24 week relief bladder pain discomfort associate interstitial cystitis .</brief_summary>
	<brief_title>Effectiveness Safety Study Pentosan Polysulfate Sodium Treatment Interstitial Cystitis</brief_title>
	<detailed_description>The purpose multi-center , double-blind ( neither patient physician know whether drug placebo take , dosage ) , randomize ( patient assign different treatment base chance ) , parallel group trial evaluate effectiveness safety two dos pentosan polysulfate sodium ( 100 mg day 100 mg three time day ) versus placebo 24 week relief bladder pain discomfort associate interstitial cystitis . The hypothesis study treatment difference proportion responder study endpoint ( Week 24 ) . Effectiveness assess base reduction O'Leary-Sant Interstitial Cystitis Symptom Index ( ICSI ) total score . Safety assessment include vital sign , laboratory test , adverse event physical exam . Patients receive one follow study treatment mouth day 24 week : pentosan polysulfate sodium 100 mg day group - one pentosan polysulfate sodium 100 mg capsule morning , one matching placebo capsule afternoon evening ; pentosan polysulfate sodium 100 mg capsule three time day group - one pentosan polysulfate sodium 100 mg capsule morning , afternoon evening ; placebo group - one placebo capsule morning , afternoon evening</detailed_description>
	<mesh_term>Cystitis</mesh_term>
	<mesh_term>Cystitis , Interstitial</mesh_term>
	<mesh_term>Pentosan Sulfuric Polyester</mesh_term>
	<criteria>Must total score 8 great O'LearySant Interstitial Cystitis Symptom Index ( ICSI ) score &gt; 0 4 question ICSI must experience bladder pain , urinary urgency urinary frequency , related urinary tract infection , least 6 month prior entry study must average &gt; = 10 void per day ( &gt; =30 void 3 consecutive day ) average &gt; = 1 void night urine culture show evidence urinary tract infection urine cytology show evidence neoplastic cell Scheduled use intravesical therapy ( eg , bladder distention , dimethyl sulfoxide ) within 4 week prior study patient cytoscopic evaluation within 4 week prior study patient currently ( within last month ) receive medication may affect symptom interstitial cystitis ( ie , antidepressant , antihistamine , antispasmodic , anticholinergic ) patient chronic user Schedule II narcotic use schedule narcotic time study entry patient take coumadin , anticoagulant , heparin , thrombolytic agent tissue plasminogen activator streptokinase</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Interstitial Cystitis</keyword>
	<keyword>Urinary Bladder Pain</keyword>
</DOC>